Ceva Santé Animale and IDT Biologika GmbH announced July 3 that Ceva successfully completed the acquisition of IDT’s veterinary biopharmaceutical and research and development activities.

With the completion, Ceva said the product portfolio will be transferred to its branding as quickly as possible, and a new global innovation center focused on swine vaccines will be created within IDT’s exiting site in Dessau, Germany.

Ceva has rapidly moved from a 33/67 bio/pharma split in 2014 to 45/55 in 2018. With addition of the IDT vaccine range and rapid growth of its own new technology vaccines, the split will be close to the 50/50 balance originally set out in its “Ambition 2020” business plan, the company said. Coupled with the complimentary tools of autogenous vaccines and improved diagnostics, this shift underlines Ceva’s belief that preventative medicine is the key to future health.

IDT’s strong range of swine vaccines will strengthen Ceva’s rapidly growing presence in this segment, the company said, noting that the deal will also boost its Veterinary Public Health product line in both food safety -- with Salmovac 440, a salmonella vaccine for chickens -- and in rabies control -- with Rabitec, an innovative, latest-generation rabies vaccine for the oral immunization of foxes and other species, which will play a crucial role in campaigns focused on the successful eradication of rabies worldwide.

IDT is set to focus on the production of human vaccines and medicines going forward.

Ceva chairman and chief executive officer Dr. Marc Prikazsky said, “Both Ceva and IDT have been driven by a deep desire to quickly develop effective vaccine solutions for our customers. It marks the 100-year heritage we share, and this, coupled with a similar entrepreneurial mindset, is what will ensure the success of the new business in the future.”

Carsten Klocke, CEO of Klocke Holding (of which IDT is a member), added, “We’re content to see our animal health business transfer into Ceva, an organization providing the optimal environment for its continued positive development. This successful transaction now allows IDT to focus on building a leading global position in biotechnological human vaccines and medicine -- a market with huge growth potential mid- and long term.”

Ceva is a French multinational veterinary pharmaceutical company created in 1999. It specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals. Ceva is present in 110 countries and employs more than 5,700 people worldwide.

IDT Biologika is a privately held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health.

Source: Ceva, which is solely responsible for the information provided and is wholly owned by the source. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.